Your browser doesn't support javascript.
loading
Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection?
Bar-Yoseph, Haggai; Daoud, Haneen; Ben Hur, Dana; Chowers, Yehuda; Waterman, Matti.
Afiliación
  • Bar-Yoseph H; Department of Gastroenterology, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel. haggaiby@gmail.com.
  • Daoud H; Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel. haggaiby@gmail.com.
  • Ben Hur D; Department of Internal Medicine H, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel.
  • Chowers Y; Department of Gastroenterology, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel.
  • Waterman M; Department of Internal Medicine H, Rambam Health Care Campus, 8th Haalia Hashnia st., 3109601, Haifa, Israel.
Int J Colorectal Dis ; 35(3): 513-519, 2020 Mar.
Article en En | MEDLINE | ID: mdl-31927638
BACKGROUND: Corticosteroids (CS) therapy to Clostridioides difficile infection (CDI) in inflammatory bowel disease (IBD) flares may worsen CDI outcomes. AIM: Assess the impact of early CS exposure on outcomes of IBD patients diagnosed with CDI. METHODS: Retrospective study of IBD patients admitted with first-time CDI between 2002 and 2018. Comparisons were made based on CS exposure 48 h from admission. Patients were further subdivided to 5 groups based on CS-antibiotics temporal exposure. The primary outcome was all-cause mortality or colectomy within 3 months. Secondary outcomes were colectomy and mortality rates at 1 year, length of stay, readmissions, bacteremia, and diarrhea improvement by day 7/discharge. Cox proportional hazard model and Kaplan-Meier curves were used to assess the effects on survival. Logistic and ordinal regressions were used to assess primary and secondary outcomes. RESULTS: One hundred thirteen patients (64 CD, 46 UC, and 3 IBDU) were included, 82 (72.5%) received early CS. At baseline, CRP was significantly lower and albumin was higher in the group not exposed to early CS. At 3 months, 4 (4.8%) patients required colectomy and 6 (5.8%) died (p = NS). Length of stay was significantly reduced among patients not exposed to early CS. All other endpoints were not associated with CS exposure. In subgroup analysis, the primary outcome was not significantly different among the sub-groups. Mortality rate at 1 year was significantly lower in patients who did not receive antibiotics for CDI. CONCLUSION: Early CS therapy in IBD patients hospitalized with CDI is not associated with worse clinical outcomes. However, additional prospective research is required.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Infecciones por Clostridium / Corticoesteroides / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Colorectal Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Infecciones por Clostridium / Corticoesteroides / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Colorectal Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Alemania